WO2001028591A3 - Injection vehicle for polymer-based formulations - Google Patents

Injection vehicle for polymer-based formulations Download PDF

Info

Publication number
WO2001028591A3
WO2001028591A3 PCT/US2000/026258 US0026258W WO0128591A3 WO 2001028591 A3 WO2001028591 A3 WO 2001028591A3 US 0026258 W US0026258 W US 0026258W WO 0128591 A3 WO0128591 A3 WO 0128591A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
formulations
injection
based formulations
injection vehicles
Prior art date
Application number
PCT/US2000/026258
Other languages
French (fr)
Other versions
WO2001028591A2 (en
Inventor
Jeffrey L Cleland
Xanthe M Lam
Franklin Okumu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to CA002387058A priority Critical patent/CA2387058C/en
Priority to JP2001531419A priority patent/JP4871470B2/en
Priority to EP00971986A priority patent/EP1220690A2/en
Priority to AU10712/01A priority patent/AU1071201A/en
Publication of WO2001028591A2 publication Critical patent/WO2001028591A2/en
Publication of WO2001028591A3 publication Critical patent/WO2001028591A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Abstract

The invention provides injection vehicles suitable for administering particulate suspensions, such as polymer-based formulations, as well as associated pharmaceutical formulations, articles of manufacture, and kits. Other aspects of the invention included methods for producing and administering pharmaceutical formulations. The injection vehicles of the invention are superior to conventional injection vehicles in that they include a pseudoplastic composition that improves injectability, which facilitates delivery of the desired dose. The injection vehicles of the invention also allow the use of smaller-bore needles than are usually necessary to inject polymer-based formulations, reducing the pain associated with injection of such formulations.
PCT/US2000/026258 1999-10-15 2000-10-16 Injection vehicle for polymer-based formulations WO2001028591A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002387058A CA2387058C (en) 1999-10-15 2000-10-16 Injection vehicle for polymer-based formulations
JP2001531419A JP4871470B2 (en) 1999-10-15 2000-10-16 Injection medium for polymer-based formulations
EP00971986A EP1220690A2 (en) 1999-10-15 2000-10-16 Injection vehicle for polymer-based formulations
AU10712/01A AU1071201A (en) 1999-10-15 2000-10-16 Injection vehicle for polymer-based formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15973999P 1999-10-15 1999-10-15
US60/159,739 1999-10-15

Publications (2)

Publication Number Publication Date
WO2001028591A2 WO2001028591A2 (en) 2001-04-26
WO2001028591A3 true WO2001028591A3 (en) 2002-03-07

Family

ID=22573810

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026258 WO2001028591A2 (en) 1999-10-15 2000-10-16 Injection vehicle for polymer-based formulations

Country Status (6)

Country Link
US (1) US7582311B1 (en)
EP (1) EP1220690A2 (en)
JP (1) JP4871470B2 (en)
AU (1) AU1071201A (en)
CA (1) CA2387058C (en)
WO (1) WO2001028591A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102830B2 (en) 2005-09-22 2015-08-11 Medivas, Llc Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use
US9144631B2 (en) 2003-01-27 2015-09-29 Benedicte Asius Ceramic-based injectable implants which are used to fill wrinkles, cutaneous depressions and scars, and preparation method thereof
US9517203B2 (en) 2000-08-30 2016-12-13 Mediv As, Llc Polymer particle delivery compositions and methods of use

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19545257A1 (en) 1995-11-24 1997-06-19 Schering Ag Process for the production of morphologically uniform microcapsules and microcapsules produced by this process
ATE376824T1 (en) 1999-01-13 2007-11-15 Alchemia Oncology Pty Ltd USE OF HYALURONAN FOR PRODUCING A MEDICATION TO INCREASE THE EFFECTIVENESS OF CYTOTOXIC DRUGS
US7651703B2 (en) * 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
WO2004057959A2 (en) 2002-12-20 2004-07-15 Generipharm, Inc. Intracutaneous injection
WO2006039704A2 (en) * 2004-09-30 2006-04-13 Janssen Pharmaceutica, N.V. Pharmaceutical composition and method for treating a joint capsule arthropathy
WO2006047279A2 (en) * 2004-10-21 2006-05-04 University Of Iowa Research Foundation In situ controlled release drug delivery system
US7951880B2 (en) * 2004-12-10 2011-05-31 University Of Iowa Research Foundation Compositions for breast implant filling and methods of use
US20060140988A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Visco-supplement composition and methods
JP5465431B2 (en) 2005-07-27 2014-04-09 アルケミア オンコロジー ピーティーワイ リミテッド Treatment protocol with hyaluronan
AU2006289651B2 (en) * 2005-09-07 2012-07-26 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
WO2007038246A2 (en) 2005-09-22 2007-04-05 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
JP5445130B2 (en) * 2006-05-02 2014-03-19 メディバス エルエルシー Delivery of ophthalmic drugs to the exterior or interior of the eye
CA2672284C (en) * 2006-12-18 2014-08-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
US20100291027A1 (en) * 2009-05-14 2010-11-18 Jason Campbell Hyaluronic acid (ha) injection vehicle
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
DE102010062288A1 (en) 2010-12-01 2012-06-06 Charité - Universitätsmedizin Berlin Use of cytokine-releasing, biodegradable particles in hyaluronic acid for the treatment of cartilage defects, in particular osteoarthrosis
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
CN105853348B (en) 2011-03-10 2019-08-30 Xeris药物公司 Parenteral injection stablizing solution
US20120237473A1 (en) * 2011-03-14 2012-09-20 University Of Medicine And Dentistry Of New Jersey Compositions And Methods For Cell Based Retinal Therapies
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
CN103748139B (en) 2011-06-23 2016-08-17 帝斯曼知识产权资产管理有限公司 For delivering the micron particle comprising biodegradable polyester-amide copolymer or the nano-particle of bioactivator
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
EP2773331B1 (en) 2011-10-31 2016-02-10 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
WO2013077357A1 (en) * 2011-11-25 2013-05-30 日本製薬株式会社 Submucosal cushioning agent
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
AU2014218512B2 (en) * 2013-02-20 2017-09-28 The University Of Queensland Conjugate compound and uses of same
CN105263476A (en) 2013-03-13 2016-01-20 库尔制药开发公司 Immune-modifying particles for the treatment of inflammation
WO2015018461A1 (en) * 2013-08-09 2015-02-12 Genbiotech Therapeutic compositions comprising hyaluronic acid
WO2016022831A1 (en) 2014-08-06 2016-02-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
EP3233067B1 (en) 2014-12-18 2019-11-06 DSM IP Assets B.V. Drug delivery system for delivery of acid sensitive drugs
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
US20160303281A1 (en) 2015-04-17 2016-10-20 Rochal Industries, Llc Composition and kits for pseudoplastic microgel matrices
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
US20190209538A1 (en) * 2016-05-05 2019-07-11 Liquidia Technologies, Inc. Precision Controlled Load and Release Particles for Post-Operative Pain
KR20240036128A (en) 2017-06-02 2024-03-19 엑스에리스 파머수티클스, 인크. Precipitation resistant small molecule drug formulations
US20220193305A1 (en) * 2019-03-29 2022-06-23 Trustees Of Tufts College Crosslinked silk fibroin-based compositions, and methods of making and using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005544A1 (en) * 1989-10-23 1991-05-02 Medinvent Drug delivery system, method for preparing the same, and use thereof
EP0633020A1 (en) * 1993-07-05 1995-01-11 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
FR2778847A1 (en) * 1998-05-20 1999-11-26 Jean Pierre Perraud Implants for sub-gingival injection comprising bio-resorbable microspheres containing an antiseptic or antibiotic

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE634668A (en) 1962-07-11
BE744162A (en) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd ENCAPSULATION PROCESS
DE2010115A1 (en) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Process for the production of micro-granules
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
JPS60100516A (en) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US4816440A (en) 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
EP0224987B1 (en) * 1985-11-29 1992-04-15 Biomatrix, Inc. Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same
JPH0725689B2 (en) * 1986-10-07 1995-03-22 中外製薬株式会社 Sustained-release preparation containing granulocyte colony-stimulating factor
US5985354A (en) * 1995-06-07 1999-11-16 Brown University Research Foundation Preparation of multiwall polymeric microcapsules from hydrophilic polymers
US4935237A (en) 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
US4937270A (en) 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5017229A (en) 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5527893A (en) 1987-09-18 1996-06-18 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
JPH01265970A (en) * 1988-04-19 1989-10-24 Shiseido Co Ltd Collagen water solution or water dispersion solution including hyaluronic acid
SE8804164A0 (en) * 1988-11-17 1990-05-18 Per Prisell Pharmaceutical preparation
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
JP3283288B2 (en) * 1991-03-08 2002-05-20 電気化学工業株式会社 Bioactive peptide preparation
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
IT1247472B (en) * 1991-05-31 1994-12-17 Fidia Spa PROCESS FOR THE PREPARATION OF MICROSPHERES CONTAINING BIOLOGICALLY ACTIVE COMPONENTS.
JPH05186364A (en) * 1991-08-01 1993-07-27 Takeda Chem Ind Ltd Water-soluble composition
CA2079509C (en) 1991-10-01 2002-05-14 Shigeyuki Takada Prolonged release microparticle preparation and production of the same
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
US5204382A (en) 1992-02-28 1993-04-20 Collagen Corporation Injectable ceramic compositions and methods for their preparation and use
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
PT686045E (en) 1993-02-23 2001-04-30 Genentech Inc STABILIZATION BY EXPIPIENTS OF POLYPEPTIDES TREATED WITH ORGANIC SOLVENTS
JP3761594B2 (en) * 1993-07-05 2006-03-29 武田薬品工業株式会社 Manufacturing method of sustained-release preparation
US5464815A (en) 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
US5643605A (en) 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
EP0741580A4 (en) 1993-12-14 2001-07-11 Univ Johns Hopkins Med Controlled release of pharmaceutically active substances for immunotherapy
US5879673A (en) 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
WO1998051348A2 (en) 1997-05-16 1998-11-19 Amgen Inc. Sustained-release delayed gels
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
TW577758B (en) * 1997-10-27 2004-03-01 Ssp Co Ltd Intra-articular preparation for the treatment of arthropathy
JP4234803B2 (en) * 1997-10-27 2009-03-04 久光製薬株式会社 Pharmaceutical composition with controlled drug release rate
FR2780730B1 (en) * 1998-07-01 2000-10-13 Corneal Ind INJECTABLE BIPHASIC COMPOSITIONS, ESPECIALLY USEFUL IN RESTORATIVE AND AESTHETIC SURGERIES
ATE376824T1 (en) * 1999-01-13 2007-11-15 Alchemia Oncology Pty Ltd USE OF HYALURONAN FOR PRODUCING A MEDICATION TO INCREASE THE EFFECTIVENESS OF CYTOTOXIC DRUGS
AU751200B2 (en) * 1999-01-18 2002-08-08 Lg Life Sciences, Ltd. Lipophilic microparticles containing a protein drug or antigen and formulation comprising same
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
DK1223990T3 (en) * 1999-10-15 2004-11-29 Inst Genetics Llc Formulations of hyaluronic acid for delivery of osteogenic proteins
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005544A1 (en) * 1989-10-23 1991-05-02 Medinvent Drug delivery system, method for preparing the same, and use thereof
EP0633020A1 (en) * 1993-07-05 1995-01-11 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
FR2778847A1 (en) * 1998-05-20 1999-11-26 Jean Pierre Perraud Implants for sub-gingival injection comprising bio-resorbable microspheres containing an antiseptic or antibiotic

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517203B2 (en) 2000-08-30 2016-12-13 Mediv As, Llc Polymer particle delivery compositions and methods of use
US9144631B2 (en) 2003-01-27 2015-09-29 Benedicte Asius Ceramic-based injectable implants which are used to fill wrinkles, cutaneous depressions and scars, and preparation method thereof
US9102830B2 (en) 2005-09-22 2015-08-11 Medivas, Llc Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use

Also Published As

Publication number Publication date
JP2004513872A (en) 2004-05-13
CA2387058C (en) 2009-01-06
AU1071201A (en) 2001-04-30
CA2387058A1 (en) 2001-04-26
EP1220690A2 (en) 2002-07-10
US7582311B1 (en) 2009-09-01
WO2001028591A2 (en) 2001-04-26
JP4871470B2 (en) 2012-02-08

Similar Documents

Publication Publication Date Title
WO2001028591A3 (en) Injection vehicle for polymer-based formulations
IL256054A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2001082899A3 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
WO2004105782A3 (en) Drug delivery systems for tumor targeting ngr-molecules and uses thereof
EP0740650A4 (en) Codrugs as a method of controlled drug delivery
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
WO2004022099A3 (en) Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
WO2001012199A3 (en) Methoxyamine potentiation of temozolomide anti-cancer activity
WO2006017852A3 (en) Pharmaceutical compositions for controlled release delivery of biologically active compounds
WO2008041245A3 (en) Injectable depot composition and it's process of preparation
IL172082A0 (en) Foamable pharmaceutical compositions and methods for treating a disorder
PL393259A1 (en) TPO mimetics, pharmaceutical compositions containing thereof, the use of these compounds for drug manufacturing, methods for preparing compounds, compositions, method for improving the stimulation of megakaryocyte maturation, method for improving survival and / or proliferation of cells and intermediate compounds
AU3957400A (en) Dry, mouldable drug formulation
WO2002070438A3 (en) Compositions for delivering bisphosphonates
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
PL1796650T3 (en) Delivery vehicle containing nanoparticles
WO2003045319A3 (en) Targeted therapeutics and uses thereof
WO2005055948A3 (en) Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders
AU2207197A (en) Targeted site specific drug delivery compositions and method of use
WO2002032378A3 (en) Fusion cells and cytokine compositions for treatment of disease
HK1098352A1 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
WO2002030399A3 (en) Polymer controlled delivery of a therapeutic agent
WO2006138316A3 (en) Methods for delivering molecules to the central nervous system
JO2296B1 (en) Substituted pyrroles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2387058

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000971986

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 531419

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000971986

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642